In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Phathom Pharmaceuticals Inc (NASDAQ: PHAT) closed at $14.94 in the last session, down -4.35% from day before closing price of $15.62. In other words, the price has decreased by -$4.35 from its previous closing price. On the day, 1.13 million shares were traded. PHAT stock price reached its highest trading level at $15.61 during the session, while it also had its lowest trading level at $14.846.
Ratios:
We take a closer look at PHAT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.19 and its Current Ratio is at 2.23.
Upgrades & Downgrades
In the most recent recommendation for this company, Cantor Fitzgerald on February 14, 2025, initiated with a Overweight rating and assigned the stock a target price of $23. On May 03, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $24. Needham reiterated its Buy rating for the stock on January 05, 2024, while the target price for the stock was revised from $23 to $26.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 03 ’25 when Breedlove Robert Charles sold 524 shares for $13.51 per share. The transaction valued at 7,079 led to the insider holds 47,407 shares of the business.
Breedlove Robert Charles sold 461 shares of PHAT for $5,573 on Sep 05 ’25. The Principal Accounting Officer now owns 47,931 shares after completing the transaction at $12.09 per share. On Jul 16 ’25, another insider, Breedlove Robert Charles, who serves as the Principal Accounting Officer of the company, sold 1,692 shares for $8.36 each. As a result, the insider received 14,152 and left with 48,392 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 1062808256 and an Enterprise Value of 1510787072. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.22. Its current Enterprise Value per Revenue stands at 10.264 whereas that against EBITDA is -7.1.
Stock Price History:
The Beta on a monthly basis for PHAT is 0.43, which has changed by 0.76696837 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, PHAT has reached a high of $16.26, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 12.46%, while the 200-Day Moving Average is calculated to be 69.69%.
Shares Statistics:
According to the various share statistics, PHAT traded on average about 1.12M shares per day over the past 3-months and 817100 shares per day over the past 10 days. A total of 71.04M shares are outstanding, with a floating share count of 41.32M. Insiders hold about 41.92% of the company’s shares, while institutions hold 50.73% stake in the company. Shares short for PHAT as of 1763078400 were 13078808 with a Short Ratio of 11.71, compared to 1760486400 on 14125695. Therefore, it implies a Short% of Shares Outstanding of 13078808 and a Short% of Float of 30.3.
Earnings Estimates
The firm’s stock currently is rated by 4.0 analysts. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.32 and low estimates of -$0.57.
Analysts are recommending an EPS of between -$2.09 and -$3.16 for the fiscal current year, implying an average EPS of -$2.41. EPS for the following year is -$0.16, with 4.0 analysts recommending between $0.4 and -$1.16.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $55.88M. It ranges from a high estimate of $57M to a low estimate of $55M. As of. The current estimate, Phathom Pharmaceuticals Inc’s year-ago sales were $29.66MFor the next quarter, 8 analysts are estimating revenue of $59.94M. There is a high estimate of $66.89M for the next quarter, whereas the lowest estimate is $54.1M.
A total of 8 analysts have provided revenue estimates for PHAT’s current fiscal year. The highest revenue estimate was $174.53M, while the lowest revenue estimate was $172.5M, resulting in an average revenue estimate of $173.39M. In the same quarter a year ago, actual revenue was $55.25MBased on 8 analysts’ estimates, the company’s revenue will be $316.85M in the next fiscal year. The high estimate is $334M and the low estimate is $290M.
